Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03785548
Other study ID # 18-107
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 15, 2019
Est. completion date July 1, 2020

Study information

Verified date July 2020
Source TriHealth Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective cohort study to determine if using a birthing mirror during the patient's pelvic examination decreases patients's degree of vulnerability and discomfort.


Description:

In Obstetrics and Gynecology and its gynecologic subspecialties, the pelvic examination is routine practice for screening and diagnostic purposes. Nevertheless, due to their intimate nature, pelvic examinations may result in loss of control, embarrassment, discomfort and anxiety.

The mirror pelvic exam has been a proposed technique to decrease patient anxiety and improve comfort during an already uncomfortable examination. However, little research has focused on this modality to date.

The purpose of this study is to investigate whether the mirror pelvic exam decreases the level of vulnerability and discomfort experienced during the pelvic examination.


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date July 1, 2020
Est. primary completion date May 29, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- New patients undergoing a pelvic exam performed by a physician at Cincinnati Urogynecology Associates, TriHealth

Exclusion Criteria:

- Existing patients

- Unwillingness to participate in the study

- Physical or mental impairment that would affect the subject's ability to visualize the mirror during examination or to complete questionnaires

- Inability to understand English

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usage of a mirror
using a mirror during the pelvic examination

Locations

Country Name City State
United States Cincinnati Urogynecology Associates Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
TriHealth Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability VAS on vulnerability level will be measured after the pelvic exam, and group difference after controlling for baseline vulnerability, will be calculated. The VAS is a validated 100 millimeter scale with 'no vulnerability' represented as 0 mm and 'very vulnerable' equating to 100 mm. 30 minutes after the pelvic exam
Primary Group Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort VAS on discomfort level will be measured after the pelvic exam, and group difference after controlling for baseline discomfort level, will be calculated. The VAS is a validated 100 millimeter scale with 'no pain' represented as 0 mm and 'most pain' equating to 100 mm. 30 minutes after the pelvic exam
See also
  Status Clinical Trial Phase
Terminated NCT05254756 - "Pilot Study: A Comparison of the Bouquet Speculum and the Traditional 2-Bladed Speculum" N/A